Abbvie pulls plug on Swedish R&D partnership
Swedish biotech firm Bioarctic expresses its disappointment over Abbvie’s decision to terminate a collaborative partnership on potential Parkinson’s treatments.
by andreas lønstrup, translated by daniel pedersen
US-based Abbvie has decided to end a collaboration with Swedish biotech firm Bioartic on the latter’s portfolio of alpha-synuclein antibodies, the company has announced in a press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Cancer drug hope raises Genmab's spirits after legal defeat
For subscribers
